DIN 02463539 — TARO-DEFERASIROX 250 MG
TARO-DEFERASIROX is a tablet for suspension of Deferasirox marketed by TARO PHARMACEUTICALS INC. The full Deferasirox monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02463539
- Brand name
- TARO-DEFERASIROX
- Active ingredient
- Deferasirox
- Strength
- 250 MG
- Dosage form
- TABLET FOR SUSPENSION
- Route
- ORAL
- Manufacturer
- TARO PHARMACEUTICALS INC
- Health Canada status
- MARKETED
- Drug class
- Iron chelating agent
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Deferasirox products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02461544 | APO-DEFERASIROX | 125 MG | TABLET FOR SUSPENSION | APOTEX INC | MARKETED |
| 02461552 | APO-DEFERASIROX | 250 MG | TABLET FOR SUSPENSION | APOTEX INC | MARKETED |
| 02461560 | APO-DEFERASIROX | 500 MG | TABLET FOR SUSPENSION | APOTEX INC | MARKETED |
| 02485273 | APO-DEFERASIROX (TYPE J) | 180 MG | TABLET | APOTEX INC | MARKETED |
| 02485281 | APO-DEFERASIROX (TYPE J) | 360 MG | TABLET | APOTEX INC | MARKETED |
| 02485265 | APO-DEFERASIROX (TYPE J) | 90 MG | TABLET | APOTEX INC | MARKETED |
| 02527782 | AURO-DEFERASIROX (TYPE J) | 180 MG | TABLET | AURO PHARMA INC | MARKETED |
| 02527790 | AURO-DEFERASIROX (TYPE J) | 360 MG | TABLET | AURO PHARMA INC | MARKETED |
| 02527774 | AURO-DEFERASIROX (TYPE J) | 90 MG | TABLET | AURO PHARMA INC | MARKETED |
| 02287420 | EXJADE | 125 MG | TABLET FOR SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02287439 | EXJADE | 250 MG | TABLET FOR SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02287447 | EXJADE | 500 MG | TABLET FOR SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02452227 | JADENU | 180 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02452235 | JADENU | 360 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02452219 | JADENU | 90 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02549840 | JAMP DEFERASIROX (TYPE J) | 180 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED |
| 02549859 | JAMP DEFERASIROX (TYPE J) | 360 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED |
| 02549832 | JAMP DEFERASIROX (TYPE J) | 90 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED |
| 02474328 | PMS-DEFERASIROX | 125 MG | TABLET FOR SUSPENSION | PHARMASCIENCE INC | MARKETED |
| 02474336 | PMS-DEFERASIROX | 250 MG | TABLET FOR SUSPENSION | PHARMASCIENCE INC | MARKETED |
| 02474344 | PMS-DEFERASIROX | 500 MG | TABLET FOR SUSPENSION | PHARMASCIENCE INC | MARKETED |
| 02528304 | PMS-DEFERASIROX (TYPE J) | 180 MG | TABLET | PHARMASCIENCE INC | MARKETED |
| 02528312 | PMS-DEFERASIROX (TYPE J) | 360 MG | TABLET | PHARMASCIENCE INC | MARKETED |
| 02528290 | PMS-DEFERASIROX (TYPE J) | 90 MG | TABLET | PHARMASCIENCE INC | MARKETED |
| 02464454 | SANDOZ DEFERASIROX | 125 MG | TABLET FOR SUSPENSION | SANDOZ CANADA INCORPORATED | MARKETED |
| 02464462 | SANDOZ DEFERASIROX | 250 MG | TABLET FOR SUSPENSION | SANDOZ CANADA INCORPORATED | MARKETED |
| 02464470 | SANDOZ DEFERASIROX | 500 MG | TABLET FOR SUSPENSION | SANDOZ CANADA INCORPORATED | MARKETED |
| 02489902 | SANDOZ DEFERASIROX (TYPE J) | 180 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED |
| 02489910 | SANDOZ DEFERASIROX (TYPE J) | 360 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED |
| 02489899 | SANDOZ DEFERASIROX (TYPE J) | 90 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED |
| 02463520 | TARO-DEFERASIROX | 125 MG | TABLET FOR SUSPENSION | TARO PHARMACEUTICALS INC | MARKETED |
| 02463547 | TARO-DEFERASIROX | 500 MG | TABLET FOR SUSPENSION | TARO PHARMACEUTICALS INC | MARKETED |
| 02507323 | TARO-DEFERASIROX (TYPE J) | 180 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED |
| 02507331 | TARO-DEFERASIROX (TYPE J) | 360 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED |
| 02507315 | TARO-DEFERASIROX (TYPE J) | 90 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED |